Validation of Digital Pathology Platform for Metabolic-Associated Steatohepatitis for Clinical Trials
H Pulaski, SS Mehta, LC Manigat, S Kaufman, H Hou… - medRxiv, 2023 - medrxiv.org
Aims: Determine if pathologic assessment of disease activity in steatohepatitis, performed
using Whole Slide Images (WSIs) on the AISight Clinical Trials platform, yields results that …
using Whole Slide Images (WSIs) on the AISight Clinical Trials platform, yields results that …
Analytical and Clinical Validation of AIM-NASH: A Digital Pathology Tool for Artificial Intelligence-based Measurement of Nonalcoholic Steatohepatitis Histology
H Pulaski, SA Harrison, SS Mehta, AJ Sanyal, MC Vitali… - medRxiv, 2024 - medrxiv.org
Metabolic-dysfunction associated steatohepatitis (MASH) is a major cause of liver-related
morbidity and mortality, yet treatment options are limited. Manual scoring of liver biopsies …
morbidity and mortality, yet treatment options are limited. Manual scoring of liver biopsies …
[HTML][HTML] Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
V Ratziu, M Hompesch, M Petitjean… - Journal of …, 2024 - journal-of-hepatology.eu
The worldwide prevalence of non-alcoholic steatohepatitis (NASH) is increasing, causing a
significant medical burden, but no approved therapeutics are currently available. NASH drug …
significant medical burden, but no approved therapeutics are currently available. NASH drug …
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions
V Ratziu, M Hompesch, M Petitjean, C Serdjebi… - Journal of …, 2023 - Elsevier
Non-alcoholic steatohepatitis (NASH) prevalence is increasing worldwide, causing a
significant medical burden, but no approved therapeutics are currently available. NASH drug …
significant medical burden, but no approved therapeutics are currently available. NASH drug …
Liver-Quant: Feature-Based Image Analysis Toolkit for Automatic Quantification of Metabolic Dysfunction-Associated Steatotic Liver Disease
M Farzi, C McGenity, A Cratchley, L Leplat… - medRxiv, 2024 - medrxiv.org
Introduction: The histological assessment of liver biopsies by pathologists serves as the gold
standard for diagnosing metabolic dysfunction-associated steatotic liver disease (MASLD) …
standard for diagnosing metabolic dysfunction-associated steatotic liver disease (MASLD) …
Estimating the Inter-and Intra-Rater Reliability for NASH Fibrosis Staging in the Presence of Bridge Ordinal Ratings with Hierarchical Bridge Category Models
The public health burden of non-alcoholic steatohepatitis (NASH), a liver condition
characterized by excessive lipid accumulation and subsequent tissue inflammation and …
characterized by excessive lipid accumulation and subsequent tissue inflammation and …
Alignment of Physician-Stated vs Clinically Derived Reference Fibrosis Score in Patients with Non-Alcoholic Steatohepatitis: A Real-World European Survey
QM Anstee, K Hallsworth, N Lynch… - Pragmatic and …, 2023 - Taylor & Francis
Objective Stratifying disease severity in patients with non-alcoholic steatohepatitis (NASH) is
essential for appropriate treatment and long-term management. Liver biopsy is the reference …
essential for appropriate treatment and long-term management. Liver biopsy is the reference …
[HTML][HTML] A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of cirrhosis
MS Sherman, PK Challa… - Hepatology …, 2024 - journals.lww.com
Background: Histopathology remains the gold standard for diagnosing and staging
metabolic dysfunction–associated steatotic liver disease (MASLD). The feasibility of studying …
metabolic dysfunction–associated steatotic liver disease (MASLD). The feasibility of studying …
Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR–MASH score
D Marti‐Aguado, J Arnouk, JX Liang… - Liver …, 2024 - Wiley Online Library
Abstract Background and Aims Diagnosis of metabolic dysfunction‐associated
steatohepatitis (MASH) requires histology. In this study, a magnetic resonance imaging …
steatohepatitis (MASH) requires histology. In this study, a magnetic resonance imaging …
[HTML][HTML] AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials
JS Iyer, H Pokkalla, C Biddle-Snead… - MedRxiv, 2023 - ncbi.nlm.nih.gov
Clinical trials in nonalcoholic steatohepatitis (NASH) require histologic scoring for
assessment of inclusion criteria and endpoints. However, guidelines for scoring key features …
assessment of inclusion criteria and endpoints. However, guidelines for scoring key features …